Physician profile
Tran Le
NPI 1023631009
$7,176.57
in general payments reported to CMS, 2019-2025
19 companies · $4,914 in 2025
The $4,914 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $67.48 · 2024: $2,195 · 2025: $4,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,311 · Food and Beverage: $2,798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,310.78 |
| Food and Beverage | $2,798.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,825.65 | 2024-2025 | Infinity, Proclaim |
| Medtronic, INC. | $1,554.71 | 2024-2025 | Percept Pc Brainsense, Activa Pc |
| Boston Scientific Corporation | $1,155.80 | 2025 | Vercise |
| Acadia Pharmaceuticals INC | $469.05 | 2024-2025 | Nuplazid |
| Abbvie INC. | $188.39 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $148.35 | 2024-2025 | Austedo Xr, Austedo Xr |
| Argenx US, INC. | $124.13 | 2025 | Vyvgart Hytrulo |
| Mdd US Operations, LLC | $99.27 | 2025 | |
| Jazz Pharmaceuticals INC. | $90.89 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $87.55 | 2024-2025 | |
| Ucb, INC. | $81.11 | 2024-2025 | Rystiggo, Fintepla |
| Otter Pharmaceuticals, LLC | $72.40 | 2025 | Sympazan |
| Merz Pharmaceuticals, LLC | $69.17 | 2024-2025 | Xeomin, Inbrija |
| Biogen, INC. | $56.90 | 2025 | Skyclarys |
| Amneal Pharmaceuticals LLC | $44.34 | 2024 | Crexont |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $38.49 | 2024-2025 | Ingrezza |
| Eisai INC. | $27.19 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.53 | 2024 | Hyqvia |
| Astrazeneca Pharmaceuticals Lp | $16.65 | 2024 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tran Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.